FDA approves sotorasib with panitumumab for colorectal cancer
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
Related Articles
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
One Surgeon’s Spirit and Brilliance Lift a Whole Community
A childhood dream became a reality for Montana native Kelly K. Hunt, MD, FACS, FSSO, who has changed the face of the surgical breast oncology…
Nirogacestat Shows Improved PFS and Quick Response in Desmoid Tumors
Mark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat.
Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis
Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Acalabrutinib Plus Bendamustine and Rituximab Receives FDA Approval in MCL
Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle cell lymphoma.
A Pioneering Journey in Radiation Oncology Inspired by Multidisciplinary Collaboration
Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.
Combination induces durable responses in advanced multiple myeloma
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination…
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…
